Serious adverse events · adults and children with uncomplicated malaria
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in serious adverse events compared with other antimalarials (moderate certainty).
1 finding from 1 review
Serious adverse events · children under 18 years of age with enteric fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults and children with enteric fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults and children with enteric fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Serious adverse events · ≥ 15‐year‐old people with late second stage human African gambiense trypanosomiasis (trypanosomes in blood or nymph node fluid and WBC >…
It is very uncertain whether the intervention changes serious adverse events (very low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · children aged 14 years or younger with uncomplicated P falciparum malaria
The intervention showed no clear difference in serious adverse events (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · adults with P vivax malaria
It is very uncertain whether the intervention changes serious adverse events (very low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · adults and children with P vivax malaria
It is very uncertain whether the intervention changes serious adverse events (very low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · adults and children with confirmed clinical and parasitological P vivax malaria
The intervention may leads to higher serious adverse events (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · adults and children with confirmed clinical and parasitological P vivax malaria
1 finding from 1 review
Intervention not reported
Serious adverse events · adults and children with confirmed clinical and parasitological P vivax malaria
1 finding from 1 review
Intervention not reported
Serious adverse events · adults and children with confirmed clinical and parasitological P vivax malaria
1 finding from 1 review
Serious adverse events · drug‐resistant pulmonary tuberculosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults with drug‐sensitive pulmonary tuberculosis
Gatifloxacin‐containing 4‐month ATT regimens showed no clear difference in serious adverse events compared with standard 6‐month ATT regimens (moderate certainty).
1 finding from 1 review
Serious adverse events · adults with drug‐sensitive pulmonary tuberculosis
Moxifloxacin‐containing 4‐month ATT regimens showed no clear difference in serious adverse events compared with standard 6‐month ATT regimen (moderate certainty).
1 finding from 1 review
Serious adverse events · adults and children of 2 years of age and older
1 finding from 1 review
Serious adverse events · adults and children of 2 years of age and older
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events · adults and adolescents with scrub typhus
1 finding from 1 review
Serious adverse events · adults with scrub typhus
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events · adults with scrub typhus
The review found no eligible studies for this question.
1 finding from 1 review